|Company name||Akorn, Inc.|
NEW YORK, November 7, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Akorn, Inc. (NASDAQ: AKRX).
In a recent ruling, a Delaware Court determined that Fresenius SE could walk away from its $4.3 billion deal to buy pharmaceutical manufacturer Akorn. Soon after the parties signed the deal documents, Akorn’s financials slumped dramatically. When Fresenius found that Akorn had breached U.S. FDA data integrity requirements, the company terminated the deal due to Akorn’s “failure to fulfill several closing conditions.” The court agreed that Fresenius validly ended the merger agreement because Akorn’s regulatory compliance representations were false.
On this news, Akorn’s shares fell more than 58%, closing at $5.36 on October 1, 2018.
If you are a long term stockholder of Akorn, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.